The fight against antimicrobial resistance: international regulatory convergence
Originally published on Clinical leader
Antimicrobial resistance (AMR) has become a serious global health concern. It is estimated that worldwide, between 2015 and 2050, roughly 10 million people will have died of infections caused by resistant bacteria. In addition to the health threat, the direct and indirect economic damage from AMR could amount to an annual loss in global GDP similar to the loss during the 2008 global financial crisis, according to the 2017 World Bank Report.
The “International Regulatory Convergence” DIAmond session brought together representatives from the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and Health Canada to discuss how regulatory agencies seek to set strategic goals and priorities for various collaborative regulatory initiatives addressing AMR. Each panel member outlined important initiatives that are on their agency’s agenda for the next two years as well as efforts to seek collaborations at an international level.